Nektar Therapeutics announced topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial evaluating rezpegaldesleukin, an investigational IL-2 pathway agonist, in patients with severe-to-very-severe alopecia areata. The study randomized 92 patients to receive one of two doses of rezpegaldesleukin or placebo via subcutaneous injection twice monthly. The primary endpoint was the mean percentage reduction from baseline in the Severity of Alopecia Tool (SALT) score at Week 36. Rezpegaldesleukin demonstrated a favorable safety and tolerability profile, with nearly all treatment-emergent adverse events reported as mild-to-moderate and self-resolving. The discontinuation rate due to adverse events was 1.4% in the combined treatment arms, and no patients discontinued due to injection site reactions. Nektar plans to submit the REZOLVE-AA results for presentation at a medical conference in 2026. Data from an ongoing 16-week treatment extension are expected in early Q2 2026.